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Abstract The treatment of metastasized renal cell carci-
noma (RCC) still represents a formidable challenge,
despite the development of small molecule, tyrosine kinase
inhibitors (TKI) that have made a major impact on the
disease. Although the percentage of patients achieving a
partial response or stabilization of disease has been
impressive, these effects are mostly non-durable. Addi-
tionally, drug-related side effects can be quite severe.
Alternative treatment modalities might be monoclonal
antibodies (mAbs). mAbs against RCC-associated antigens
have been developed and have shown promise. Addition-
ally, current efforts focus on Bevacizumab that recognizes
vascular endothelial growth factor (VEGF). VEGF over-
expression in RCC provides the opportunity to inhibit this
proangiogenic pathway. Also with Bevacizumab, promis-
ing results have been obtained, particularly in combination
with other treatment modalities. It is likely that mAbs,
either as single agents or in combination with other agents,
may become useful additions to the armamentarium to
diagnose and treat RCC.
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Introduction
The hypothesis by Ehrlich in early 1900s that malignant
cells express unique structures that can be used to guide
cytotoxic therapy to tumors [1] followed by the develop-
ment of the hybridoma technique by Kohler and Milstein
almost 70 years later [2] has led to the development of anti-
cancer reagents with unique characteristics. One of the
most distinguishing factors is the possibility to select
monoclonal antibodies (mAbs) recognizing target mole-
cules with very restricted expression in normal tissues. To
date, tumor-speciﬁc antigens (antigens expressed on all
tumor cells of a particular tumor type not expressed by
normal cells) have not been identiﬁed. The members of the
so-called cancer-testis family do exhibit highly tissue-
restricted expression, but are considered promising target
molecules for cancer vaccines, less for antibody therapy,
particularly in view of the extreme intra- and inter-tumor
heterogeneity [3].
Similar to other malignancies, monoclonal antibodies
(mAbs) targeting renal cell carcinoma (RCC) associated
molecules were developed without understanding the
molecular events underlying RCC [4–8]. The increased
understanding of molecular events important in the carci-
nogenesis of RCC led to the recognition that these
aberrations can be used to target RCC. Speciﬁcally, aber-
rant von Hippel-Lindau (VHL) gene expression has been
identiﬁed as a general event in clear cell RCC (ccRCC) [9],
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DOI 10.1007/s00345-008-0236-5which represents 80–85% of localized cases and 90–95%
of metastatic RCC (mRCC). The loss of a functional VHL
gene product leads to accumulation of the transcription
factor HIF-1a that is an obligatory element for the tran-
scription of several genes. This includes vascular
endothelial growth factor (VEGF) and carbonic anhydrase
9 (CA9), targets for which most clinical experience with
mAbs in RCC has been generated (Bevacizumab and
G250, respectively).
The rationale and effects of Bevacizumab and G250-
directed therapy are fundamentally different: Bevacizumab
treatment leads to VEGF-depletion and consequently to
diminished neovascularization followed by tumor cell
death, mainly due to loss of vascularization. In contrast,
G250 treatment targets the cell surface of RCC cells where
it must exert toxic effects. Both approaches have advan-
tages and disadvantages. Bevacizumab treatment has the
advantage that VEGF depletion can be achieved in the
circulation, and homing to all tumor vessels is not neces-
sary. However, other regulatory pathways can also lead to
neovascularization and small, non-vascularized tumor loci
will not be affected. G250 treatment has the advantage that
RCC cells can be targeted, irrespective of tumor size.
However, in view of the generally poor perfusion rate and
high interstitial ﬂuid pressure in RCC, deep penetration of
tumors may be difﬁcult. Also, since G250-binding alone
does not confer a lytic signal to RCC cells, tumor cell kill
requires effector cells or coupling of G250 to toxic agents.
Bevacizumab
Bevacizumab is a humanized mAb against VEGF that
binds and neutralizes all of the major isoforms of VEGF
[10]. This prevents VEGF from interacting with its recep-
tors and activation of downstream signaling pathways. This
mode of action is thought to lead to regression of existing
microvasculature, normalization of mature vasculature, and
inhibition of the production of new vasculature [11].
Whether all these effects are true for RCC is unclear at the
moment.
Signiﬁcant protein dose levels are needed to maintain
sufﬁciently high Bevacizumab levels to trap VEFG, the
target of Bevacizumab. The ﬁrst Bevacizumab trial in
metastatic RCC (mRCC) patients addressed whether Bev-
acizumab treatment could lengthen the time to progression
of disease and the response rate [12]. Survival was a sec-
ondary end point. In this randomized phase II trial, 116
patients with metastatic, refractory clear cell RCC were
randomized to placebo, low-dose (3 mg/kg) Bevacizumab,
or high-dose (10 mg/kg) Bevacizumab given intravenously
every 2 weeks. All patients had prior disease progression
while on systemic treatment; the vast majority had received
prior interleukine-2. Patients with disease progression on
placebo crossed over to receive low-dose Bevacizumab.
Bevacizumab treatment resulted in a signiﬁcant prolonga-
tion of the time to progression of disease in the high-dose
antibody group (4.8 months as compared with 2.5 months).
Possibly, the low-protein dose was inadequate to sufﬁ-
ciently deplete circulating VEGF levels in-between
injections, explaining the poor outcome in this group. The
study was inadequately powered to show a signiﬁcant
difference in overall survival between groups. Based on
this encouraging result, Bevacizumab has been combined
with other treatment modalities to augment the therapeutic
index.
Bevacizumab in combination
The AVOREN trial investigated the effects of standard
therapy of interferon alfa-2a plus placebo or interferon
alfa-2a plus Bevacizumab, administered every 2 weeks at
a dose of 10 mg/kg [13]. In this randomized, double blind
phase III trial, 649 patients with ﬁrst-line mRCC were
enrolled. The primary analysis endpoint was assessment
of improvement in progression-free survival (PFS),
deﬁned as the length of time the tumor did not grow or
patient death did not occur. Other endpoints of the study
included overall survival, time to progression, time to
treatment failure, overall response rate, and safety proﬁle.
The addition of Bevacizumab to IFN-a2a signiﬁcantly
increased PFS (10.2 vs. 5.4 months) and objective tumor
response rate (30.6 vs. 12.4%; P\0.0001). Additionally,
the combination treatment showed a trend toward
improved overall survival (P = 0.0670), which leads to
the conclusion that the combination of Bevacizumab with
IFN-a2a is superior to either of the single treatment
regimens in mRCC. The working mechanism explaining
the superiority of this combination treatment has not been
deﬁned yet, but most likely the superiority is the net
effect of the reduction of the immunosuppressive effects
due to decreased VEGF levels combined with the
immunomodulatory effects of IFN.
Considering that the epidermal growth factor receptor
(EGFR) is also overexpressed in RCC, a multicenter, phase
II study evaluated the addition of erlotinib (Tarceva), an
EGFR inhibitor, to Bevacizumab in metastatic RCC
patients [14]. Treatment consisted of 10 mg/kg Bev-
acizumab given intravenously every 2 weeks and 150 mg
erlotinib given orally each day. With 15 (25%) patients
showing objective responses, and an additional 36 patients
(61%) with stable disease after 8 weeks of treatment, a
randomized phase II trial was performed evaluating Bev-
acizumab + placebo versus Bevacizumab + erlotinib.
Disappointingly, identical response rates and PFS rates for
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EGFR-targeting is of any beneﬁt.
The effect of Bevacizumab and low-dose interleukine-2
(IL-2) in mRCC was evaluated in a phase II trial in pre-
viously untreated, good and intermediate risk, mRCC
patients. Patients received 8-week cycles of IL-2
(250,000 U/kg per day s.c. Day 1–5 during week 1 and
125,000 U/kg per day s.c. Day 1–5 during weeks 2–6,
followed by a 2 week break), and Bevacizumab 10 mg/kg
was administered i.v. every 2 weeks starting on day-14.
With 16 of the planned 35 patients enrolled, and 11
evaluable patients for response, 1 partial response (PR) and
3 stable disease (SD) lasting [3 months were observed
[16]. All patients with SD demonstrated some degree of
tumor shrinkage. Similar to the working mechanism of the
Bevacizumab/IFN combination, the anti-tumor effects are
possibly the result of the reduction of the immunosup-
pressive effects due to decreased VEGF levels combined
with the general immune activating effects of IL-2. Inter-
estingly, treated patients demonstrated an increase in the
number of regulatory T cells without effect on DC acti-
vation. Larger, randomized studies will be necessary to
address the value of this combination treatment.
In a phase I trial, Bevacizumab has also been combined
with sunitinib (Sutent
), a tyrosine kinase inhibitor, with
the hypothesis that this combination may increase antitu-
mor efﬁcacy by maximizing inhibition of the VEGF
pathway. The Bevacizumab dose was kept constant
(10 mg/kg) while the sunitinib dose was escalated starting
at 25 mg (escalation with 12.5 mg increments). Of 13
patients evaluated for best response, 4 had partial respon-
ses, 7 had stable disease, and 2 had PD [17].
Similarly, the combination of Bevacizumab and the
mTOR inhibitor CCI-779 (Temsirolimus
) has been
investigated. Patients received 25 mg/week Temsirolimus
and 5 or 10 mg/kg Bevacizumab. In 12 evaluable patients,
7 PR and 3 SD were observed [18]. The encouraging
results certainly deserve further testing of these combina-
tions in phase II trials.
Monoclonal antibody G250
G250 is a mAb against CA9, a molecule which is ubiqui-
tously expressed in ccRCC [19]. CA9 expression in non-
ccRCC has also been documented, and there, it is most
likely a reﬂection of (sustained) hypoxia [20]. Clinical
efforts with mAb G250 in RCC have focused on radio-
immunotherapy and passive immunotherapy. This mAb
was described as a mAb recognizing an RCC-associated
antigen, absent in normal kidney and homogeneously
expressed in most RCC [4], most notably clear cell RCC
[19]. In 2000, the G250 antigen molecule was identiﬁed
and shown to be CA9 [21]. The molecular characterization
allowed transcriptional regulation studies that revealed a
strict dependence of G250 expression on HIF-1a [22].
Thus, the molecular mechanism responsible for CAIX
expression in ccRCC is similar to VEGF, namely due to
non-functional VHL protein leading to HIF-1a accumula-
tion and gene expression.
The ﬁrst clinical trials with mAbG250 were already
performed and published before the molecular character-
ization of G250 antigen was achieved. The combined data
from the immunohistochemical tissue distribution, animal
experiments and ex vivo perfusion of tumor bearing kid-
neys had provided sufﬁcient evidence to initiate a biopsy-
based phase I protein dose escalation trial with murine
mAbG250. The rationale of G250-directed therapy obvi-
ously differs from Bevacizumab: Bevacizumab treatment
leads to VEGF-depletion and consequently to diminished
neovascularization whereas G250 treatment targets RCC
cells directly. This ﬁrst mAbG250 clinical trial demon-
strated various pivotal aspects: most notably, virtually no
uptake in other tissues resulting in excellent tumor visu-
alization, and very high tumor uptake [23].
The G250 antibody uptake that was observed was up to
10-fold higher than any other mAb uptake in solid tumors,
which led to the design of a phase I/II radioimmunotherapy
(RIT) trial with murine mAbG250. RIT led to stabilization
of disease in 17 of 33 patients, with tumor shrinkage
observed in two patients. Transient liver toxicity was
observed, quite likely the result of mAbG250 liver uptake,
although there was no correlation between the amount of
131I administered or hepatic absorbed radiation dose and
the extent and nature of hepatic toxicity [24].
Because the murine G250 antibody was highly immu-
nogenic, restricting multiple injections, mAbG250 was
chimerized. The results of the phase I protein dose esca-
lation trial with chimeric G250 (cG250) basically
duplicated the results from the murine G250 trial: virtually
no uptake in other tissues resulting in excellent tumor
visualization, and very high tumor uptake. The half-life of
the antibody was extended, as was to be expected, but,
more importantly, the chimerized from of G250 was almost
immunosilent [25]. Thus, multiple injections became pos-
sible. Various phase I and phase II trials have been
performed with cG250 aimed at therapeutic intervention.
Based on the very high uptake levels, several RIT trials
were performed. In the ﬁrst phase I trial with
131I-cG250,
one patient showed a partial response ([9 months) [26]
which set the stage for phase II RIT trials in metastatic
RCC patients. RIT studies with single high dose
131I-G250,
rapid fractionated dose
131I-G250 [27], and sequential high
dose
131I-G250 [28] have resulted in only occasional
therapeutic responses, although dosimetric analyses sug-
gest that tumor-sterilizing levels can be reached. Even two
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131I-G250 did not
result in objective responses, but in stabilization of previ-
ously progressive disease in a few patients. RIT with G250
has been accompanied by bone marrow toxicity similar to
mAb RIT in other tumor types and considering the minimal
beneﬁt,
131I-based RIT with cG250 have been abandoned.
Since RCC is a radiotherapy resistant tumor, possibly even
higher radiation doses are necessary to achieve tumor-
sterilizing levels. Current G250 RIT efforts are directed to
177-lutetium and 90-yttrium labeled G250. It is hypothe-
sized that the use of more powerful radionuclides that are
also better retained in the tumor cells may lead to clinical
responses. Animal experiments have demonstrated the
superiority of
177Lu- and
90Y-labeled G250 over
131I-G250
[29]. Importantly, stabilization of previously progressive
disease has been observed in almost all
177Lu-G250 treated
patients, although the maximum tolerable
177Lu dose has
not been achieved. Dosimetric analyses of the ﬁrst patients
treated with
177Lu-G250 suggest that indeed tumor-steril-
izing levels may be achieved. Figure 1 illustrates targeting
of
177Lu-G250 in a patient with metastatic renal cancer.
In view of the obvious tumor-speciﬁc accumulation of
cG250, passive immunotherapy of RCC patients has also
been studied extensively. In vitro mAbG250 can elicit
antibody-dependent cellular cytotoxicity (ADCC), which
can be enhanced by low dose IL-2 [30]. Various (non-
randomized) clinical trials have now been completed with
cG250 alone, and in combination with IL2 or interferon
[31, 32]. Thus far, these treatments appear to lead to
extended survival time. The apparent clinical beneﬁt
appears to be quite substantial with a documented median
survival of 22 months in patients with metastatic RCC who
have progressive disease at study entry. Nevertheless, it is
difﬁcult to judge the value of this treatment. Clearly, ran-
domized trials are necessary to unequivocally demonstrate
whether passive immunotherapy with cG250 is of beneﬁt
for metastatic RCC patients.
The largest trial, which is currently ongoing, is the
adjuvant ARISER trial (adjuvant Rencarex immunotherapy
phase III trial to study efﬁcacy in nonmetastatic renal cell
carcinoma). In this phase III randomized, double blind,
placebo-controlled trial, patients with ECOG performance
status of 0 with completely resected primary clear cell RCC
and no evidence of remaining local or distant disease, are
treated. The study is designed to detect a signiﬁcant dif-
ference between the two treatment arms with respect to
disease-free survival; patients will be followed-up long-
term to determine overall survival statistics.
Recently, the potential utility of mAbG250 as a diag-
nostic imaging agent was investigated [33]. The excellent
imaging capability had been noted in almost all patients,
but this line of research was not pursued mainly because
detection of suspect renal masses and occult metastatic
RCC was not deemed advantageous. Additionally, treat-
ment modalities for metastasized RCC were poor, and,
therefore, efforts focused on treatment. However, with a
steady increase of incidentally discovered renal masses and
new therapeutic modalities becoming available, imaging
might become of importance to distinguish more poten-
tially malignant tumours from less aggressive variants. In
the ﬁrst prospective clinical trial with
124I-labeled cG250, a
very high speciﬁcity and sensitivity to identify ccRCC in
patients with suspect renal masses was demonstrated, a
clear indication of the potential clinical utility. Whether
Fig. 1 Anterior (left) and posterior (right) whole body scans acquired
7 days post-injection of patient injected with
177Lu-cG250. Please
note high uptake in both pulmonary lesions and in contralateral
kidney lesions. Uptake in liver is due to the conjugation methodology
and is not related to G250 antigen expression
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remains to be determined.
In conclusion, it is reasonable to assume that Bev-
acizumab and G250 monoclonal antibodies either as single
agents or in combination with other agents may become
useful additions to the armamentarium to diagnose and
treat (cc)RCC. Several trials evaluating the combination of
G250 or Bevacizumab with registered RCC treatments are
currently in progress and will further deﬁne the role of
these mAbs in RCC.
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